Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.57−0.08 (-1.50%)
Close on Nov 17, 2026Market cap $482.87MP/E –Yield –
Valneva total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Valneva's total debt was €184.06M at Jun 30, 2026. For fiscal 2025 it was €179.17M, down 4.4% from the year before. The highest annual figure on record is €187.37M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €179.17M | -4.4% |
| FY2024 | Dec 31, 2024 | €187.37M | +6.0% |
| FY2023 | Dec 31, 2023 | €176.85M | +79.0% |
| FY2022 | Dec 31, 2022 | €98.81M | +70.8% |
| FY2021 | Dec 31, 2021 | €57.83M | +8.4% |
| FY2020 | Dec 31, 2020 | €53.36M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €184.06M | +9.3% |
| Q1 FY2026 | Mar 31, 2026 | €182.33M | +0.6% |
| Q4 FY2025 | Dec 31, 2025 | €179.17M | -4.4% |
| Q3 FY2025 | Sep 30, 2025 | €167.72M | -2.8% |
| Q2 FY2025 | Jun 30, 2025 | €168.39M | -6.7% |
| Q1 FY2025 | Mar 31, 2025 | €181.18M | -0.1% |
| Q4 FY2024 | Dec 31, 2024 | €187.37M | +6.0% |
| Q3 FY2024 | Sep 30, 2024 | €172.58M | +22.5% |
| Q2 FY2024 | Jun 30, 2024 | €180.42M | +89.1% |
| Q1 FY2024 | Mar 31, 2024 | €181.45M | +86.3% |
| Q4 FY2023 | Dec 31, 2023 | €176.85M | +79.0% |
| Q3 FY2023 | Sep 30, 2023 | €140.86M | +33.1% |
| Q2 FY2023 | Jun 30, 2023 | €95.41M | +21.4% |
| Q1 FY2023 | Mar 31, 2023 | €97.39M | +63.0% |
| Q4 FY2022 | Dec 31, 2022 | €98.81M | +70.8% |
| Q3 FY2022 | Sep 30, 2022 | €105.86M | +98.4% |
| Q2 FY2022 | Jun 30, 2022 | €78.60M | – |
| Q1 FY2022 | Mar 31, 2022 | €59.74M | – |
| Q4 FY2021 | Dec 31, 2021 | €57.83M | – |
| Q4 FY2020 | Dec 31, 2020 | €53.36M | – |
See a number that looks wrong?